icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025
Back grey_arrow_rt.gif
 
 
 
ECLIPSE: A Pivotal Program Evaluating Once-Monthly Combination Therapy With Tobevibart and Elebsiran for Chronic HDV Infection - Rationale, Study Design, and Objectives
 
 
 
AASLD 2025 Nov 7-11 Wash DC
 
Nancy Reau,1 Pietro Lampertico,2,3 Tarik Asselah,4 Michael A. Chattergoon,5 Tamara Palagashvili,5 Richie Phan,5 Cara Pilowa,5 Todd Correll5 1Division of Digestive Diseases and Nutrition, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA; 2Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; 3CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; 4Université de Paris Cité, Hôpital Beaujon, AP-HP, INSERM UMR1149, Paris, France; 5Vir Biotechnology, Inc., San Francisco, CA, USA.

1112251

1112252

1112253

1112254